Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.
Also called NCT04534439
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 140 participants
- Sponsor
- Aptabio Therapeutics, Inc.
- Registry
-
NCT04534439 -
2019-004155-37
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Bulgaria, Czechia, Hungary, Serbia
- Registry status
- Completed
Technical summary
Registry record NCT04534439. Randomized; quadruple masking; primary purpose treatment. Start 2020-08-24 (actual); primary completion 2021-07-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy
- Condition
- Diabetic Nephropathies
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Nephropathy, Diabetic
- Intervention (Drug)
- APX-115
- Intervention (Drug)
- Placebo
- Lead sponsor
- Aptabio Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct04534439- Content hash
c165c55bf60cce9ac539d5a3a6185173517447a491645d15fc2fcfdc903ca75d